Dezecapavir
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Dezecapavir
- Molecular weight
- 918.2
- Structure (SMILES)
- Cn1nc(NS(C)(=O)=O)c2c(Cl)ccc(-n3c([C@H](Cc4cc(F)cc(F)c4)NC(=O)Cn4nc(C(F)F)c5c4C(F)(F)[C@@H]4C[C@H]54)nc4nc(OCCC(F)(F)F)ccc4c3=O)c21
- dezecapavir
- Dezecapavir
- dezecapavir [INN]
- dezecapavir inn
- vh 4011499
- vh 4011499a
- VH-4011499
- VH-4011499A
- vh4011499
- Vh4011499
- VH4011499
- CAS registry numbers
- 2570323-59-8
- ChEMBL ID
- CHEMBL6068048
- InChIKey
- JBJQTRRKPQLQQB-VWPQPMDRSA-N
- PubChem compound IDs
- 155427795
- FDA ingredient codes (UNII)
- SEK9LN2LSM
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -vir
- Condition
- Virus Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000763
- Subject identifier
- D014777
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition identifier
- EFO_0000763
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005108
- NCT05393271
- NCT06012136
- NCT06039579
- NCT06368986
- Hydrogen bond acceptors
- 12
- Hydrogen bond donors
- 2
- Polar surface area
- 167.92
- Calculated partition coefficient (ALogP)
- 6.74
- Calculated partition coefficient (XLogP)
- 6.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 3
- Rotatable bonds
- 13
- Heavy atoms
- 62
- Molecular formula
- C37H29ClF9N9O5S
- Monoisotopic mass
- 917.1557174
- Natural product
- No
Related records
Trials (5)
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults
- A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants
- First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants
- Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults
In development for (2)
- HIV infectious disease Phase 2
- Viral infectious disease Phase 2